Design Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 5, 2024

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Six Months Ended June 30,
	2024	2023
Cash flows from operating activities
Net loss	$(22,898)	$(39,231)
Reconciliation of net loss to net cash used in operating activities:
Depreciation	294	262
Stock-based compensation	6,483	7,145
Amortization of premiums on investment securities, net	(3,304)	(2,539)
Non-cash lease expense	8	20
Change in operating assets and liabilities:
Prepaid expense and other assets	(1,039)	1,790
Accounts payable and other liabilities	(3,243)	1,325
Net cash used in operating activities	(23,699)	(31,228)
Cash flows from investing activities
Purchases of investment securities	(99,290)	(95,984)
Proceeds from maturities of investment securities	147,595	127,875
Purchases of property and equipment	(356)	(176)
Net cash provided by investing activities	47,949	31,715
Cash flows from financing activities
Issuance of common stock through employee stock purchase plan	223	206
Proceeds from the exercise of stock options	26	4
Net cash provided by financing activities	249	210
Net increase in cash and cash equivalents	24,499	697
Cash and cash equivalents at beginning of period	21,200	26,500
Cash and cash equivalents at end of period	$45,699	$27,197

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.